BioCentury
ARTICLE | Clinical News

AGIX reports preliminary Phase II data

May 21, 2001 7:00 AM UTC

AtheroGenics (AGIX) said preliminary results from a double-blind, placebo-controlled, 305-patient CART-1 Phase II study in Canada showed coronary arteries from patients treated with AGI-1067 had greater luminal diameters six months after angioplasty (the primary end point) than patients given placebo. AGIX has not yet determined whether the trial showed statistical significance on the primary end point, and said a full analysis of the safety and efficacy data will be announced later this year. According to CFO Mark Colonnese, the compound showed a benefit in luminal diameter during the two weeks prior to angioplasty. However, the primary end point included only measures starting from angioplasty and ending six months later. ...